Experienced in Splenomegaly

Dr. Olatoyosi M. Odenike

Hematology Oncology | Hematology | Oncology
The University Of Chicago
400 Skokie Blvd, Suite 300, 
Northbrook, IL 
Accepting New Patients
Offers Telehealth
Experienced in Splenomegaly
The University Of Chicago
400 Skokie Blvd, Suite 300, 
Northbrook, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olatoyosi Odenike is a Hematologist Oncology specialist and a Hematologist in Northbrook, Illinois. Dr. Odenike is rated as an Experienced provider by MediFind in the treatment of Splenomegaly. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Myelofibrosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Odenike is currently accepting new patients.

Her clinical research consists of co-authoring 128 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
400 Skokie Blvd, Suite 300, Northbrook, IL 60062
Other Locations
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia
Phase 1 Study of Venetoclax in Combination With Decitabine 10-Day Regimen in Subjects With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drugs: Decitabine, Venetoclax
Study Phase: Phase 1
A Phase II Study of Decitabine in Myelofibrosis
A Phase II Study of Decitabine in Myelofibrosis
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2025
Intervention Type: Drug, Other
Study Drug: Decitabine
Study Phase: Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

128 Total Publications

Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies.
Journal: British journal of haematology
Published: September 05, 2025
Similar Doctors
Anita Pandey
Advanced in Splenomegaly
Dr. Anita Pandey
Hematology | Oncology
Advanced in Splenomegaly
Dr. Anita Pandey
Hematology | Oncology

Northwest Oncology And Hematology SC

800 Biesterfield Road, Suite 210, Enter Building 5 Next To ER. Take Elevators On The Left Up To 2nd Floor., 
Elk Grove, IL 
 (13.9 miles away)
847-870-4100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anita Pandey is a Hematologist and an Oncologist in Elk Grove, Illinois. Dr. Pandey is rated as an Advanced provider by MediFind in the treatment of Splenomegaly. Her top areas of expertise are Breast Cancer, Malabsorption, Thrombocytopenia, and Leukocytosis.

Bety C. Ciobanu
Advanced in Splenomegaly
Dr. Bety C. Ciobanu
Hematology | Oncology
Advanced in Splenomegaly
Dr. Bety C. Ciobanu
Hematology | Oncology

Illinois Cancer Specialists

7447 W Talcott Ave, 
Chicago, IL 
 (10.8 miles away)
773-774-0042
Languages Spoken:
English, Romanian
See accepted insurances
Offers Telehealth

Bety Ciobanu is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Ciobanu is rated as an Advanced provider by MediFind in the treatment of Splenomegaly. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Agranulocytosis, and Chronic Familial Neutropenia.

Erol I. Yorulmazoglu
Experienced in Splenomegaly
Dr. Erol I. Yorulmazoglu
Hematology | Oncology
Experienced in Splenomegaly
Dr. Erol I. Yorulmazoglu
Hematology | Oncology

Northwest Oncology And Hematology SC

800 Biesterfield Road, Suite 210, Enter Building 5 Next To ER. Take Elevators On The Left Up To 2nd Floor., 
Elk Grove, IL 
 (13.9 miles away)
847-885-4100
Languages Spoken:
English, Spanish, Turkish
See accepted insurances
Offers Telehealth

Erol Yorulmazoglu is a Hematologist and an Oncologist in Elk Grove, Illinois. Dr. Yorulmazoglu is rated as a Distinguished provider by MediFind in the treatment of Splenomegaly. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, and Familial Colorectal Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odenike's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile